Drug Profile

Research programme: phosphatidylinositol-3-kinase inhibitors - Traws Pharma

Alternative Names: ON 146; ON 146040

Latest Information Update: 04 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Onconova Therapeutics
Developer Traws Pharma
Class Antineoplastics; Small molecules
Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Discontinued Burkitt's lymphoma; Chronic myeloid leukaemia; Mantle-cell lymphoma; Multiple myeloma

02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
25 Apr 2023 Discontinued - Preclinical for Burkitt's lymphoma in USA (unspecified route)
25 Apr 2023 Discontinued - Preclinical for Chronic myeloid leukaemia in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com